The 1997 ANAO audit reveals that the industry was focused on comparator selection, the incorporation of wider qualitative economic benefits in the evaluation process, and the need to reduce submission churn to accelerate new listings. Sound familiar? …
The last audit shows why more process will never lead to faster access
July 26, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Former Speaker of the House appointed as official Patron of Rare Cancers Australia
March 25, 2025 - - Latest News -
Another day, and another addition to what is now a motherload of bad ideas
March 25, 2025 - - Latest News -
Australian eye therapy company now focused on survival after clinical trial result
March 25, 2025 - - Latest News -
Mark Butler: Patients waiting too long and 'as the Health Minister, of course, I am sorry for that'
March 24, 2025 - - Latest News -
What happens to the conspiracy when the industry and ministerial criticisms sound remarkably similar?
March 24, 2025 - - Latest News -
Nanotechnology could improve odds in treating aggressive breast cancers
March 24, 2025 - - Latest News -
Call for safety net change with half a million Australians missing out on cheaper medicines
March 24, 2025 - - Latest News